Preparation of a novel adenovirus formulation with artificial envelope of multilayer polymer-coatings: Therapeutic effect on metastatic ovarian cancer

Oncology Reports

Volumn 23, Issue 3, 2010, Pages 733-738

  Yoshihara, Chieko ^a   Hamada, Katsuyuki ^b   Koyama, Yoshiyuki ^a  

^a OTSUMA WOMEN'S UNIVERSITY   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Artificial envelope; Gene therapy; Layer by layer; Oncolytic adenovirus; Ovarian cancer

Indexed keywords

ADENOVIRUS VECTOR; ONCOLYTIC ADENOVIRUS; POLYMER; VIRUS ANTIBODY;

ANIMAL CELL; ARTICLE; ASCITES; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; INOCULATION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REPORTER GENE; THERAPY EFFECT; VIRAL GENE THERAPY; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NEOPLASM METASTASIS; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; POLYETHYLENEIMINE;

EID: 77349088004     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000691     Document Type: Article

References (16)

1. Kreppel F and Kochanek S: Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 16: 16-29, 2007.
2. Alemany R and Curiel DT: CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 8: 1347-1353, 2001.
3. Johnson M, Huyn S, Burton J, Sato M and Wu L: Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther 17: 1262-1269, 2006.
4. Muruve DA: The innate immune response to adenovirus vectors. Hum Gene Ther 15: 1157-1166, 2004.
5. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV and Kaye SB: Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/ refractory epithelial ovarian cancer. J Clin Oncol 20: 1562-1569, 2002.
6. Muller CY, Coleman RL, Rogers P, Merritt JA, Parker K and Miller DS: Phase I intraperitoneal adenoviral p53 gene transfer in ovarian cancer. Proc Am Soc Clin Oncol 20: Abs 1025, 2001.
7. Hamada K, Desaki J, Nakagawa K, Zhang T, Shirakawa T, Gotoh A and Tagawa M: Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther 15: 1121-1128, 2007.
8. O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE and Francis GE: PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 10: 1349-1358, 1999.
9. Alemany R, Suzuki K and Curiel DT: Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 81: 2605-2609, 2000.
10. 3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. J Nucl Med 47: 130-139, 2006.
11. Croyle M, Chirmule N, Zhang Y and Wilson J: 'Stealth' adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 75: 4792-4801, 2001.
12. Dodds E, Piper T, Murphy S and Dickson G: Cationic lipids and polymers are able to enhance adenoviral infection of cultured mouse myotubes. J Neurochem 72: 2105-2112, 1999.
13. McKay T, MacVinish L, Carpenter B, Themis M, Jezzard S, Goldin R, Pavirani A, Hickman ME, Cuthbert AW and Coutelle C: Selective in vivo transfection of murine biliary epithelia using polycation-enhanced adenovirus. Gene Ther 7: 644-652, 2000.
14. Lanuti M, Kouri C, Force S, Chang M, Amin K, Xu K, Blair I, Kaiser LR and Albelda S: Use of protamine to augment adenovirus-mediated cancer gene therapy. Gene Ther 6: 1600-1610, 1999.
15. Hamada K, Kohno S, Iwamoto M, Yokota H, Okada M, Tagawa M, Hirose S, Yamasaki K, Shirakata Y, Hashimoto K and Ito M: Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy. Cancer Res 63: 2506-2512, 2003.
16. Trubetskoy VS, Loomis A, Slattum PM, Hagstrom JE, Budker VG and Wolff JA: Caged DNA does not aggregate in high ionic strength solutions. Bioconjugate Chem 10: 624-628, 1999.